Enrofloxacin use in a long-distance transport model of equine respiratory disease.

Abstract

Successful clinical management of bacterial pneumonia in horses depends on the administration of an appropriate antimicrobial agent at an adequate dosage and frequency, given by the correct route of administration for an adequate duration. Empiric antimicrobial therapy should be based on the clinician's experience and current veterinary literature. Based on the frequency of Gram-positive bacterial pathogens isolated from horses with bacterial pneumonia, every effort should be made to provide antimicrobial coverage for this class of pathogens. Gram-negative pathogens may co-exist; therefore, broad spectrum antimicrobial coverage may be necessary. Antimicrobial agents posing potential drug related risks (e.g. nephrotoxicity in dehydrated patients, peracute colitis in racehorses) may not be appropriate for empiric use and enrofloxacin offers an enhanced spectrum of antimicrobial activity with reduced risk of complication. Our findings indicate that in cases of exclusive Gram-positive respiratory disease, solo therapy with enrofloxacin is not indicated.